Toboroz
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Jamie Mull, Site 0168
Fut, nem toboroz
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
NCT03419234· 2. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Toboroz
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
NCT03067181· 3. fázis· Children's Oncology Group· Forrás
Fut, nem toboroz
Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery
NCT02775851· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT02834013· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
NCT02954874· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Breast Cancer WEight Loss Study (BWEL Study)
NCT02750826· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Fut, nem toboroz
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
NCT02642042· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
NCT02785952· 3. fázis· SWOG Cancer Research Network· Forrás
Fut, nem toboroz
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
NCT02339571· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
NCT02595424· 2. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Fut, nem toboroz
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
NCT02445391· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Fut, nem toboroz
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
NCT02224781· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02465060· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Fut, nem toboroz
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
NCT02306161· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
NCT02194738· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread
NCT02196181· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT01896999· 1/2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT01863550· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás